Shanghai FOSUN Pharmaceutical (Group) Co., Ltd. (SHSE:600196) will use the proceed of the share issue to repay interest-bearing debts, replenish the working capital of the group, and finance potential mergers and acquisitions domestically or overseas.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.04 CNY | +1.63% |
|
+3.92% | -7.95% |
12/07 | Fosun Pharma Receives Offers for Share Alternative Offer Related to Henlius Merger Offer | MT |
08/07 | Shanghai Fosun Pharmaceutical (Group) Cancer Treatment Gets NMPA's Nod for Clinical Trials | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.95% | 754.78Cr | |
+55.35% | 85TCr | |
+31.64% | 63TCr | |
-0.10% | 36TCr | |
+15.47% | 32TCr | |
+13.10% | 30TCr | |
+15.51% | 24TCr | |
+16.72% | 23TCr | |
+16.54% | 18TCr | |
+4.31% | 17TCr |
- Stock Market
- Equities
- 600196 Stock
- News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
- Shanghai FOSUN Mulls Acquisitions